Last $6.03 USD
Change Today +0.24 / 4.15%
Volume 216.1K
ALIM On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

alimera sciences inc (ALIM) Snapshot

Open
$5.80
Previous Close
$5.79
Day High
$6.05
Day Low
$5.80
52 Week High
01/17/14 - $8.44
52 Week Low
12/12/13 - $2.14
Market Cap
267.1M
Average Volume 10 Days
234.2K
EPS TTM
$-0.80
Shares Outstanding
44.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALIMERA SCIENCES INC (ALIM)

alimera sciences inc (ALIM) Related Businessweek News

No Related Businessweek News Found

alimera sciences inc (ALIM) Details

Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company’s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

31 Employees
Last Reported Date: 03/7/14
Founded in 2003

alimera sciences inc (ALIM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $505.7K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $352.8K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $333.4K
Compensation as of Fiscal Year 2013.

alimera sciences inc (ALIM) Key Developments

Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Belgium for the Treatment of Chronic Diabetic Macular Edema

Alimera Sciences, Inc. announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN(R) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Approval in Belgium marks the fourth European approval through the Repeat-Use application procedure and the 12th approval worldwide, including the recent U.S. approval for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). To date, ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom and Germany. ILUVIEN is pending approval in an additional six European Union (E.U.) countries included in the Repeat-Use application procedure. These countries are the Czech Republic, Finland, Ireland, Luxembourg, the Netherlands and Poland.

Alimera Sciences, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Alimera Sciences, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenue of $2,408,000 compared to $758,000 a year ago. GAAP net loss applicable to common stockholders was approximately $7.0 million, compared with GAAP net loss applicable to common stockholders of approximately $1.1 million for the third quarter of 2013. Net loss before taxes was $6,964,000 compared to $1,113,000 a year ago. Basic and diluted net loss per share was $0.17 compared to $0.04 a year ago. Non-GAAP adjusted net loss attributable to common stockholders was $8,894,000 compared to $7,850,000 a year ago. Non-GAAP adjusted net loss per share basic and diluted was $0.22 compared to $0.25 a year ago. For the nine months, the company reported net revenue of $6,682,000 compared to $937,000 a year ago. Net loss before taxes was $26,538,000 compared to $31,456,000 a year ago. Net loss was $26,652,000 compared to $31,456,000 a year ago. Basic and diluted net loss per share was $0.68 compared to $1.15 a year ago. Non-GAAP adjusted net loss attributable to common stockholders was $22,190,000 compared to $25,748,000 a year ago. Non-GAAP adjusted net loss per share basic and diluted was $0.57 compared to $0.82 a year ago.

Alimera Sciences, Inc. to Report Q3, 2014 Results on Nov 06, 2014

Alimera Sciences, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALIM:US $6.03 USD +0.24

ALIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALIM.
View Industry Companies
 

Industry Analysis

ALIM

Industry Average

Valuation ALIM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALIMERA SCIENCES INC, please visit www.alimerasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.